Product Description: Although surgical and catheter-based revascularization techniques have substan­ tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance...read more

Product Description: In den letzten Jahren haben Hemmstoffe des Konversionsenzyms bei der Indikation hoher Blutdruck, Herzinsuffizienz und bei Zustanden nach Myokardinfarkt eine Dif ferentialtherapie erlaubt, die in ihren Ergebnissen bemerkenswert ist und uber eine Organ protektion zur Senkung der Mortalitat dieser letalen kardiovaskularen Erkrankungen beigetragen haben...read more

Product Description: It is an exciting task to be the editor of the first monograph covering a new area of the biomedical sciences. Since the first report in 1980 by Robert Furchgott and colleagues (see Chapter 1) of the evidence of endothelium-dependent relaxation in isolated arteries, there are ever­ increasing numbers of vascular physiologists and pharmacologists who are scraping away the endothelium to look into its role in cardiovascular con­ trol...read more

Product Description: It has been almost 15 years since the fIrst reports appeared indicating that adenosine exerted a .protective effect in ischemic and reperfused myocardium. Numerous experimental studies have shown that adenosine (both exogenous and endogenous adenosine) delays the onset of ischemic contracture, modulates myocardial metabolism during ischemia, attenuates reversible postischemic ventricular dysfunction (myocardial stunning), and reduces myocardial infarct size...read more

(view table of contents)

Although the importance of calcium (Ca2+) in the maintenance of cardiac contractility was recognized as early as 1880, the critical role of the ion in the contractile process in skeletal, cardiac, and smooth muscle has only been established within the last three decades. As the complexity of the pharmacological actions of the Ca2+ channel inhibitors grows, there is a continued need to further clarify the inhibitors, both chemically and functionally. This volume provides an update of the field based on the work presented at the 5th International Symposium on Calcium Antagonists: Pharmacology and Clinical Research. It reviews the current state of the growing area of molecular biology of Ca2+ channels. In the cardiovascular area, in addition to the well-established clinical uses of Ca2+ channel inhibitors, exciting new work pointing to an application in atherosclerosis is described. The book also includes important uses of Ca2+ antagonists in novel areas of interest such as the gastrointestinal tract, renal protection and multi-drug resistance.

Product Description: Although approximately one million cardiac arrests occur every year in the USA and Europe, cardiac arrest remains a clinical condition still characterised by poor prognosis. One possible explanation may be the fact that although 70 per cent of cardiac arrests take place in out-of-hospital settings, the majority of the victims do not receive basic life support (BLS) prior to the arrival of emergency medical services (EMS)...read more

HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume...

Product Description: Nitrates remain among the most commonly used therapeutic agents in cardiology. That they can re­ lieve pain in angina pectoris has been known at least since 1867, when Lauder Brunton described their clinical use. Now, almost 130 years later, we are constantly learning more about their optimal use in anginal syndromes...read more

Product Description: A unique overview of all major angiographic lipid intervention trials, presented by their principal investigators. Basic mechanisms and methodological aspects, including biochemical as well as angiographic aspects, are discussed by experts in these fields...read more

Product Description: Calcium antagonists are now regarded as the most important advance in cardiac drug therapy since the advent of beta-adrenergic blocking agents. Acting ba­ sically as vasodilators-though with many other com­ plex mechanisms especially in the case of the anti­ arrhythmic calcium antagonists, these agents have grown in importance to become among the therapeutic agents of first choice for angina pectoris and hyper­ tension...read more

No dust jacket and there is writing on the inside of the front and back. There is highlighting and underlining inside. But the book itself is solid and very readable.

The new edition of this market-leading cardiac drug resource equips you with the latest advances in cardiovascular pharmacology, one of the most rapidly changing areas of medicine. It not only offers in-depth information on all of the drug classes used to treat heart disease, but also covers new drug classes, drug use for single and multiple problem management, and more. Dynamic full-color drawings illustrate key pharmacological and physiological actions, and a user-friendly organization directs you to the information you need. An increased emphasis on the practical use of drugs saves you valuable time in researching relevant information. A companion website offers access to the fully searchable book online, enabling you to quickly search the complete contents via drug, disease or drug action...wherever and whenever you need it.Includes online access to a companion website where you can quickly search the complete contents of the book by drug, disease, or drug action. Features the practice-proven experience of two well-known editors who represent the best possible combination of clinical and research expertise in cardiovascular therapeutics. Offers easy-to-access, useful information on when to use each drug―and for what conditions―in a chapter entitled “Which Drug for Which Disease.” Discusses the management of single diseases and multiple comorbidities. Summarizes each drug class at the end of chapters to expedite reference. Incorporates all-new drugs, preparations, and clinical trial data in each chapter, equipping you to make the most up-to-date, informed clinical decisions. Offers anytime, anywhere online access to the complete contents of the book –fully searchable-, along with downloadable image library, references linked to Medline, at expertconsult.com. Offers expanded coverage of comorbid diseases through new chapters on metabolic syndrome, hyperglycemia, and diabetes. Features an increased emphasis on the practical use of drugs through highlighted sections and key illustrations, saving you time in searching for relevant information. Presents the work of several new contributors who represent a broad international perspective to equip you with a global view of cardiovascular pharmacology. Your purchase entitles you to access the web site until the next edition is published, or until the current edition is no longer offered for sale by Elsevier, whichever occurs first. If the next edition is published less than one year after your purchase, you will be entitled to online access for one year from your date of purchase. Elsevier reserves the right to offer a suitable replacement product (such as a downloadable or CD-ROM-based electronic version) should access to the web site be discontinued.

(view table of contents)